Lifeward Ltd. held an Extraordinary General Meeting of Shareholders on March 12, 2026. Shareholders approved the issuance of ordinary shares in connection with the Oratech Pharma acquisition and related financings, approved the election of two directors effective at the closing of the acquisition, approved compensation for external directors, approved an increase in shares available under the 2025 Incentive Compensation Plan, approved an equity grant to Chief Executive Officer Mark Grant, and approved the reappointment of Kost Forer Gabbay & Kasierer (Ernst & Young Global) as independent registered public accounting firm for the year ending December 31, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-000875), on March 13, 2026, and is solely responsible for the information contained therein.
Comments